TLDR
- Invivyd stock jumps 20.85% after $125M public offering announcement.
- Invivyd secures $125M for pipeline growth, RSV & COVID-19 research.
- $125M raise boosts Invivyd’s pipeline, stock surges 20.85%.
- Invivyd’s $125M offering to fund key vaccine and antibody projects.
- Invivyd sees stock surge after announcing $125M capital raise for growth.
Invivyd, Inc. (IVVD) saw a notable 20.85% surge in its stock price, closing at $2.84, following its announcement of a $125 million underwritten public offering.
Invivyd, Inc., IVVD
The biopharmaceutical company revealed it would offer 44 million shares at $2.50 per share, along with pre-funded warrants to purchase an additional 6 million shares. This news has generated significant investor interest as the company plans to use the proceeds for its pipeline programs and upcoming product launches.
Details of the Offering and Expected Proceeds
Invivyd’s latest public offering involves 44 million shares of common stock priced at $2.50 each, and pre-funded warrants to buy 6 million additional shares at nearly the same price. The company expects to raise around $125 million in gross proceeds, which will go toward various strategic initiatives. These include the development of VYD2311, efforts related to respiratory syncytial virus (RSV), and research into Long COVID and COVID-19 Post-Vaccination Syndrome.
In addition to the 44 million shares, Invivyd granted underwriters a 30-day option to purchase up to an additional 7.5 million shares. This could further increase the offering’s total size. Cantor Fitzgerald & Co. is acting as the sole book-running manager, while H.C. Wainwright & Co. serves as lead manager.
Use of Proceeds to Fuel Growth and Development
The company plans to allocate the net proceeds from the offering to various business needs. These include advancing research on monoclonal antibodies and preparing for the potential launch of VYD2311, a treatment with emergency use authorization from the FDA. Invivyd aims to continue its efforts in vaccine development, addressing diseases like RSV and measles, and further studying the impact of monoclonal antibodies on COVID-related conditions.
The proceeds will also support general corporate needs, including working capital. This capital infusion allows Invivyd to continue expanding its pipeline and to make necessary commercial preparations as it positions itself for future product launches. The company’s recent surge in stock price indicates positive sentiment in the market about its future prospects.
Background on Invivyd and Its Pipeline
Invivyd, Inc. is a biopharmaceutical firm focused on creating innovative solutions for viral diseases, especially COVID-19. The company’s proprietary technology platform enables it to develop monoclonal antibody treatments. Invivyd’s work has gained attention following its March 2024 receipt of emergency use authorization for one of its mAb candidates from the U.S. FDA.
This public offering follows a strategic period of development for the company. By securing substantial funds, Invivyd is now in a strong position to push forward its research initiatives. The successful pricing of the offering and subsequent stock price increase highlight the market’s confidence in Invivyd’s growth trajectory and future product pipeline.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
